Role of non-classical MHC class I molecules in cancer immunosuppression
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cheever, 2009, The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research, Clin Cancer Res, 15, 5323, 10.1158/1078-0432.CCR-09-0737
Girardi, 2001, Regulation of cutaneous malignancy by gammadelta T cells, Science, 294, 605, 10.1126/science.1063916
Smyth, 2000, Differential tumor surveillance by natural killer (NK) and NKT cells, J Exp Med, 191, 661, 10.1084/jem.191.4.661
Geraghty, 1987, A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment, Proc Natl Acad Sci U S A, 84, 9145, 10.1073/pnas.84.24.9145
Koller, 1988, HLA-E. A novel HLA class I gene expressed in resting T lymphocytes, J Immunol, 141, 897, 10.4049/jimmunol.141.3.897
Geraghty, 1990, Human leukocyte antigen F (HLA-F). An expressed HLA gene composed of a class I coding sequence linked to a novel transcribed repetitive element, J Exp Med, 171, 1, 10.1084/jem.171.1.1
Castelli, 2011, A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution, Mol Biol Evol, 28, 3069, 10.1093/molbev/msr138
Carosella, 2003, HLA-G molecules: from maternal-fetal tolerance to tissue acceptance, Adv Immunol, 81, 199, 10.1016/S0065-2776(03)81006-4
Rizzo, 2013, Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding, Mol Cell Biochem, 381, 243, 10.1007/s11010-013-1708-5
Carosella, 2008, Beyond the increasing complexity of the immunomodulatory HLA-G molecule, Blood, 111, 4862, 10.1182/blood-2007-12-127662
Shiroishi, 2006, Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer, J Biol Chem, 281, 10439, 10.1074/jbc.M512305200
Grimsley, 2002, Definitive high resolution typing of HLA-E allelic polymorphisms: Identifying potential errors in existing allele data, Tissue Antigens, 60, 206, 10.1034/j.1399-0039.2002.600302.x
Diehl, 1996, Nonclassical HLA-G molecules are classical peptide presenters, Curr Biol, 6, 305, 10.1016/S0960-9822(02)00481-5
LeMaoult, 2005, Immuno-tolerogenic functions of HLA-G: relevance in transplantation and oncology, Autoimmun Rev, 4, 503, 10.1016/j.autrev.2005.04.006
Bland, 2003, Requirement of the proteasome for the trimming of signal peptide-derived epitopes presented by the nonclassical major histocompatibility complex class I molecule HLA-E, J Biol Chem, 278, 33747, 10.1074/jbc.M305593200
Braud, 1997, The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9, Eur J Immunol, 27, 1164, 10.1002/eji.1830270517
Braud, 1998, TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide, Curr Biol, 8, 1, 10.1016/S0960-9822(98)70014-4
Mazzarino, 2005, Identification of effector-memory CMV-specific T lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion, Eur J Immunol, 35, 3240, 10.1002/eji.200535343
Yan, 2009, Induction of both membrane-bound and soluble HLA-G expression in active human cytomegalovirus infection, J Infect Dis, 200, 820, 10.1086/604733
Rizzo, 2007, HLA-G expression is a fundamental prerequisite to pregnancy, Hum Immunol, 68, 244, 10.1016/j.humimm.2006.10.012
Zarkhin, 2010, Expression of soluble HLA-G identifies favorable outcomes in liver transplant recipients, Transplantation, 90, 1000, 10.1097/TP.0b013e3181f546af
Verbruggen, 2006, Soluble HLA-G in rheumatoid arthritis, Hum Immunol, 67, 561, 10.1016/j.humimm.2006.03.023
LeMaoult, 2003, Biology and functions of human leukocyte antigen-G in health and sickness, Tissue Antigens, 62, 273, 10.1034/j.1399-0039.2003.00143.x
Crispim, 2008, Human leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection, Transpl Immunol, 18, 361, 10.1016/j.trim.2007.10.010
Lafon, 2005, Modulation of HLA-G expression in human neural cells after neurotropic viral infections, J Virol, 79, 15226, 10.1128/JVI.79.24.15226-15237.2005
Paul, 2000, HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression, Hum Immunol, 61, 1177, 10.1016/S0198-8859(00)00154-3
Rouas-Freiss, 2005, HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?, Cancer Res, 65, 10139, 10.1158/0008-5472.CAN-05-0097
Agaugué, 2011, Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17, Blood, 117, 7021, 10.1182/blood-2010-07-294389
Caumartin, 2006, Intercellular exchanges of membrane patches (trogocytosis) highlight the next level of immune plasticity, Transpl Immunol, 17, 20, 10.1016/j.trim.2006.09.032
Caumartin, 2007, Trogocytosis-based generation of suppressive NK cells, EMBO J, 26, 1423, 10.1038/sj.emboj.7601570
LeMaoult, 2007, Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells, Blood, 109, 2040, 10.1182/blood-2006-05-024547
Ugurel, 2001, Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy, Cancer, 92, 369, 10.1002/1097-0142(20010715)92:2<369::AID-CNCR1332>3.0.CO;2-U
Rebmann, 2002, Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients, Int J Cancer, 100, 580, 10.1002/ijc.10524
Singer, 2003, HLA-G is a potential tumor marker in malignant ascites, Clin Cancer Res, 9, 4460
Rebmann, 2003, Secretion of sHLA-G molecules in malignancies, Semin Cancer Biol, 13, 371, 10.1016/S1044-579X(03)00028-2
Lila, 2001, Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism, Proc Natl Acad Sci U S A, 98, 12150, 10.1073/pnas.201407398
Emeagi, 2013, Lentiviral vectors: a versatile tool to fight cancer, Curr Mol Med, 13, 602, 10.2174/1566524011313040011
Gobin, 1999, Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element, J Immunol, 163, 1428, 10.4049/jimmunol.163.3.1428
Moreau, 1999, IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes, Int Immunol, 11, 803, 10.1093/intimm/11.5.803
Urosevic, 2001, Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production, Am J Pathol, 159, 817, 10.1016/S0002-9440(10)61756-7
González, 2012, The immunosuppressive molecule HLA-G and its clinical implications, Crit Rev Clin Lab Sci, 49, 63, 10.3109/10408363.2012.677947
Contini, 2003, Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation, Eur J Immunol, 33, 125, 10.1002/immu.200390015
Fons, 2006, Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells, Blood, 108, 2608, 10.1182/blood-2005-12-019919
Le Bouteiller, 2007, Soluble HLA-G and control of angiogenesis, J Reprod Immunol, 76, 17, 10.1016/j.jri.2007.03.007
LeMaoult, 2005, HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells, FASEB J, 19, 662, 10.1096/fj.04-1617fje
Bukur, 2003, Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response, Hum Immunol, 64, 1081, 10.1016/j.humimm.2003.08.350
Paul, 1998, HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance, Proc Natl Acad Sci U S A, 95, 4510, 10.1073/pnas.95.8.4510
Ristich, 2005, Tolerization of dendritic cells by HLA-G, Eur J Immunol, 35, 1133, 10.1002/eji.200425741
Liang, 2008, Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6--STAT3 signaling pathway, Proc Natl Acad Sci U S A, 105, 8357, 10.1073/pnas.0803341105
Iwaszko, 2011, Clinical significance of the HLA-E and CD94/NKG2 interaction, Arch Immunol Ther Exp (Warsz), 59, 353, 10.1007/s00005-011-0137-y
Coupel, 2007, Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation, Blood, 109, 2806, 10.1182/blood-2006-06-030213
Dong, 2003, Soluble nonclassical HLA generated by the metalloproteinase pathway, Hum Immunol, 64, 802, 10.1016/S0198-8859(03)00093-4
Derré, 2006, Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells, J Immunol, 177, 3100, 10.4049/jimmunol.177.5.3100
Teklemariam, 2012, Full-length HLA-G1 and truncated HLA-G3 differentially increase HLA-E surface localization, Hum Immunol, 73, 898, 10.1016/j.humimm.2012.06.007
Ulbrecht, 1999, Cell surface expression of HLA-E: interaction with human beta2-microglobulin and allelic differences, Eur J Immunol, 29, 537, 10.1002/(SICI)1521-4141(199902)29:02<537::AID-IMMU537>3.0.CO;2-6
Ulbrecht, 1992, Impaired intracellular transport and cell surface expression of nonpolymorphic HLA-E: evidence for inefficient peptide binding, J Exp Med, 176, 1083, 10.1084/jem.176.4.1083
Wada, 2004, The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues, Eur J Immunol, 34, 81, 10.1002/eji.200324432
Michaëlsson, 2002, A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition, J Exp Med, 196, 1403, 10.1084/jem.20020797
Li, 2001, Induction of TCR Vbeta-specific CD8+ CTLs by TCR Vbeta-derived peptides bound to HLA-E, J Immunol, 167, 3800, 10.4049/jimmunol.167.7.3800
Rabot, 2005, HLA class I/NK cell receptor interaction in early human decidua basalis: possible functional consequences, Chem Immunol Allergy, 89, 72, 10.1159/000087914
Jiang, 2010, HLA-E-restricted regulatory CD8(+) T cells are involved in development and control of human autoimmune type 1 diabetes, J Clin Invest, 120, 3641, 10.1172/JCI43522
Marín, 2003, Analysis of HLA-E expression in human tumors, Immunogenetics, 54, 767, 10.1007/s00251-002-0526-9
Wischhusen, 2005, HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo, J Neuropathol Exp Neurol, 64, 523, 10.1093/jnen/64.6.523
Levy, 2008, Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer, Int J Oncol, 32, 633
Gooden, 2011, HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes, Proc Natl Acad Sci U S A, 108, 10656, 10.1073/pnas.1100354108
Wei, 1990, Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue, Hum Immunol, 29, 131, 10.1016/0198-8859(90)90076-2
Le Bouteiller, 1996, Antigen-presenting function(s) of the non-classical HLA-E, -F and -G class I molecules: the beginning of a story, Res Immunol, 147, 301, 10.1016/0923-2494(96)89643-X
Ishitani, 2003, Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition, J Immunol, 171, 1376, 10.4049/jimmunol.171.3.1376
Fiszer, 1997, Analysis of HLA class Ib gene expression in male gametogenic cells, Eur J Immunol, 27, 1691, 10.1002/eji.1830270715
Lee, 2010, HLA-F is a surface marker on activated lymphocytes, Eur J Immunol, 40, 2308, 10.1002/eji.201040348
Lepin, 2000, Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors, Eur J Immunol, 30, 3552, 10.1002/1521-4141(200012)30:12<3552::AID-IMMU3552>3.0.CO;2-L
Boyle, 2006, Selective export of HLA-F by its cytoplasmic tail, J Immunol, 176, 6464, 10.4049/jimmunol.176.11.6464
Lee, 2003, HLA-F surface expression on B cell and monocyte cell lines is partially independent from tapasin and completely independent from TAP, J Immunol, 171, 5264, 10.4049/jimmunol.171.10.5264
Gobin, 2000, Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G, Hum Immunol, 61, 1102, 10.1016/S0198-8859(00)00198-1
Noguchi, 2004, Detection of anti-HLA-F antibodies in sera from cancer patients, Anticancer Res, 24, 3387
Zhang, 2013, Alteration of HLA-F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma, Int J Cancer, 132, 82, 10.1002/ijc.27621
Lin, 2011, HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer, Lung Cancer, 74, 504, 10.1016/j.lungcan.2011.04.006
Contini, 2000, Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction, Hum Immunol, 61, 1347, 10.1016/S0198-8859(00)00212-3
Bossard, 2012, HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression, Int J Cancer, 131, 855, 10.1002/ijc.26453
Wolpert, 2012, HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells, J Neuroimmunol, 250, 27, 10.1016/j.jneuroim.2012.05.010
Allard, 2011, Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer, PLoS One, 6, e21118, 10.1371/journal.pone.0021118
Kren, 2012, Multifunctional immune-modulatory protein HLA-E identified in classical Hodgkin lymphoma: possible implications, Pathol Res Pract, 208, 45, 10.1016/j.prp.2011.11.004
Benevolo, 2011, High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis, J Transl Med, 9, 184, 10.1186/1479-5876-9-184